USD 0.03
(6.67%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 32.65 Million USD | -15.27% |
2022 | 38.53 Million USD | -14.37% |
2021 | 45 Million USD | 12.11% |
2020 | 40.14 Million USD | -0.38% |
2019 | 40.29 Million USD | 176.18% |
2018 | 14.59 Million USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 35.81 Million USD | 0.46% |
2024 Q2 | 27.9 Million USD | -23.4% |
2023 Q3 | 38.22 Million USD | -0.23% |
2023 FY | 32.65 Million USD | -15.27% |
2023 Q4 | 35.89 Million USD | -6.09% |
2023 Q2 | 38.31 Million USD | -0.25% |
2023 Q1 | 38.4 Million USD | -0.33% |
2022 Q3 | 38.51 Million USD | -0.08% |
2022 Q2 | 38.54 Million USD | -14.84% |
2022 Q1 | 45.26 Million USD | 0.57% |
2022 FY | 38.53 Million USD | -14.37% |
2022 Q4 | 38.53 Million USD | 0.06% |
2021 Q2 | 44.48 Million USD | 10.61% |
2021 FY | 45 Million USD | 12.11% |
2021 Q1 | 40.21 Million USD | 0.17% |
2021 Q4 | 45 Million USD | 0.6% |
2021 Q3 | 44.73 Million USD | 0.58% |
2020 Q2 | 40.15 Million USD | -0.18% |
2020 FY | 40.14 Million USD | -0.38% |
2020 Q1 | 40.22 Million USD | -0.18% |
2020 Q4 | 40.14 Million USD | 0.04% |
2020 Q3 | 40.12 Million USD | -0.06% |
2019 FY | 40.29 Million USD | 176.18% |
2019 Q4 | 40.29 Million USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2018 FY | 14.59 Million USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Biotricity, Inc. | 10.85 Million USD | -200.797% |
Cell MedX Corp. | - USD | -Infinity% |
Dynatronics Corporation | 3.25 Million USD | -902.124% |
Nemaura Medical Inc. | 3.08 Million USD | -957.568% |
PetVivo Holdings, Inc. | 1.01 Million USD | -3111.037% |
RetinalGenix Technologies Inc. | - USD | -Infinity% |
Sonendo, Inc. | 14.03 Million USD | -132.661% |
Telesis Bio, Inc. | 5.26 Million USD | -519.738% |
Talis Biomedical Corporation | 16.78 Million USD | -94.531% |
Viveve Medical, Inc. | 5.12 Million USD | -537.276% |